These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 37283514)

  • 1. Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Guo S; Jin F; Zheng A
    Endocr Relat Cancer; 2023 Aug; 30(8):. PubMed ID: 37283514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis.
    Zhang Z; Zhao X; Chen J
    Front Pharmacol; 2024; 15():1438288. PubMed ID: 39329126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect and safety of CDK4/6 inhibitors combined endocrine therapy on HR+, HER2-breast cancer: a meta-analysis of randomized controlled trials.
    Huang T; He Y; Yu C; Mao F; Si Y
    Endokrynol Pol; 2023; 74(1):89-105. PubMed ID: 36704980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
    Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
    JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.
    Hong K; Yao L; Sheng X; Ye D; Guo Y
    Oncol Res Treat; 2021; 44(10):557-567. PubMed ID: 34515204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK4/6 Inhibitors in Combination With Hormone Therapy for HR
    Deng Y; Ma G; Li W; Wang T; Zhao Y; Wu Q
    Clin Breast Cancer; 2018 Oct; 18(5):e943-e953. PubMed ID: 29804650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials.
    Gao HF; Lin YY; Zhu T; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
    Breast; 2021 Oct; 59():165-175. PubMed ID: 34271289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 4 and 6 inhibitors in combination with neoadjuvant endocrine therapy in estrogen receptor-positive early breast cancer: a systematic review and meta-analysis.
    Guan Y; Shen G; Fang Q; Xin Y; Huo X; Li J; Zhao F; Ren D; Liu Z; Li Z; Zhao J
    Clin Exp Med; 2023 Jun; 23(2):245-254. PubMed ID: 35304677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 inhibitors as adjuvant treatment for hormone receptor-positive, HER2-negative early breast cancer: a systematic review and meta-analysis.
    Agostinetto E; Vian L; Caparica R; Bruzzone M; Ceppi M; Lambertini M; Pondé N; de Azambuja E
    ESMO Open; 2021 Apr; 6(2):100091. PubMed ID: 33743330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, advanced breast cancer: a systematic review and meta-analysis.
    Dai Q; Wang Y; Liao M; Chen H
    Ann Palliat Med; 2022 Dec; 11(12):3727-3742. PubMed ID: 36635998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2- advanced breast cancer: a phase III RCTs based meta-analysis.
    Luo C; Yu K; Luo X; Lian T; Liu X; Xu W; Jin Z
    BMC Cancer; 2024 Aug; 24(1):1031. PubMed ID: 39169295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis.
    Zheng J; Wu J; Wang C; Zhuang S; Chen J; Ye F
    PLoS One; 2020; 15(6):e0233571. PubMed ID: 32497134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of adjuvant CDK4/6 inhibitors in hormone receptor-positive breast cancer: a systematic review and meta-analysis.
    Ergun Y; Dogan M; Ucar G; Karacin P; Karacin C
    Expert Opin Pharmacother; 2023; 24(17):1901-1909. PubMed ID: 37701962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
    Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- breast cancer: an umbrella review.
    Pu D; Xu D; Wu Y; Chen H; Shi G; Feng D; Zhang M; Liu Z; Li J
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):16. PubMed ID: 38240835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and network meta-analysis.
    Han Y; Wang J; Wang Z; Xu B
    Curr Probl Cancer; 2020 Dec; 44(6):100606. PubMed ID: 32446638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
    Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.